

AMENDMENTS TO THE CLAIMS

Please replace the currently pending claims with the following listing of claims:

1-42. (Canceled)

43. (Canceled) ~~A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier.~~

2 ~~44~~. (Currently amended) The method according to claim ~~46~~¹~~43~~, wherein the subject is human.

45. (Canceled) ~~A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier in an effective amount.~~

1 ~~46~~. (Previously presented) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 in an effective amount.

3 ~~47~~. (Previously presented) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID No:1 or SEQ ID NO:2 in an effective amount.

4 ~~48~~. (Currently amended) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody which binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, ~~A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, and B3F6.17, and B11H8.4~~ bind in an effective amount.

49. (Canceled)

5 ~~50~~. (Currently amended) The method according to claim ~~46~~¹43, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

51-58. (Canceled)

6 ~~59~~. (Currently amended) The method of claim ~~46~~¹43, wherein the antibody is a humanized antibody.

7 ~~60~~. (Currently amended) The method of claim ~~46~~¹43, wherein the antibody is a human antibody.

61. Canceled.

8 ~~62~~. (Currently amended) The A method of claim 43 inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that, wherein the antibody specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 and a pharmaceutically acceptable carrier.

9 ~~63~~. (Currently amended) The method of claim ~~46~~¹~~43~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

10 ~~64~~. (Currently amended) The method of claim ~~46~~¹~~43~~, wherein the antibody is a full length antibody.

11 ~~65~~. (Currently amended) The method of claim ~~46~~¹~~43~~, wherein the antibody is a single chain antibody.

12 ~~66~~. (Currently amended) The method of claim ~~46~~¹~~43~~, wherein the antibody is conjugated to a chemotherapeutic agent.

13 ~~67~~. (Currently amended) The method of claim ~~46~~¹~~43~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

14 ~~68~~. (Currently amended) The method of claim ~~66~~¹², wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

15 ~~69~~. (Currently amended) The antibody method of claim ~~68~~¹⁴, wherein the agent is a maytansinoid.

16 ~~70~~. (Currently amended) The A method of claim 43, inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal wherein the antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2, wherein the which antibody or fragment is conjugated to a maytansinoid, and a pharmaceutically acceptable carrier.

17 ~~71~~. (Currently amended) The A method of claim 43 inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.

~~18~~ ~~72~~. (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto selected from the group of epitopes to which an antibody antibodies produced by hybridoma hybridomas selected from the group consisting of A10B2.18 and B3F6.17 binds, and a pharmaceutically acceptable carrier.

~~19~~ ~~73~~. (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 and which is capable of internalizing Cripto.

~~20~~ ~~74~~. (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID NO:1 or SEQ ID NO:2, and a pharmaceutically acceptable carrier.

~~21~~ ~~75~~. (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas selected from the group consisting of A6.C12.11, A8G3.5, and A6F8.6 bind, and a pharmaceutically acceptable carrier.

~~22~~ ~~76~~. (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 which and inhibits the interaction of Cripto and ALK4.

~~23~~ ~~77~~ (Currently amended) The A method of ~~claim 43~~ inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal, wherein the antibody that binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, and B3F6.17, and B11H8.4 bind, and a pharmaceutically acceptable carrier.

78. (Canceled) ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the extracellular domain spanning amino acid residues 31-188 of SEQ ID NO:1 or SEQ ID NO:2.~~

79. (Canceled) ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the ligand receptor binding domain spanning amino acid residues 75-150 of SEQ ID NO:1 or SEQ ID NO:2.~~

80. (Canceled) ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the EGF-like domain spanning amino acid residues 75-112 of SEQ ID NO:1 or SEQ ID NO:2.~~

~~24~~ ~~81~~ (New) A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of Cripto to which an antibody produced by hybridoma A10B2.18 binds, and a pharmaceutically acceptable carrier.

~~25~~ ~~82~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2, wherein the antibody is conjugated to a maytansinoid, in an effective amount.

~~26~~ ~~83~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a humanized version of the antibody produced by the hybridoma B3F6.17 in an effective amount.

~~27~~ ⁸⁴ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma B3F6.17 binds in an effective amount.

~~28~~ ⁸⁵ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma A10B2.18 binds in an effective amount.

~~29~~ ⁸⁶ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and is capable of internalizing Cripto in an effective amount.

~~30~~ ⁸⁷ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6.C12.11, A8G3.5, and A6F8.6 bind in an effective amount.

~~31~~ ⁸⁸ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and inhibits the interaction of Cripto and ALK4 in an effective amount.

3

~~32~~ ⁸⁹ (New) The method according to claim ~~47~~, wherein the subject is human.

3

~~33~~ ⁹⁰ (New) The method according to claim ~~47~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

³
~~34~~ ~~91~~. (New) The method of claim ~~47~~, wherein the antibody is a humanized antibody.

³
~~35~~ ~~92~~. (New) The method of claim ~~47~~, wherein the antibody is a human antibody.

³
~~36~~ ~~93~~. (New) The method of claim ~~47~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

³
~~37~~ ~~94~~. (New) The method of claim ~~47~~, wherein the antibody is a full length antibody.

³
~~38~~ ~~95~~. (New) The method of claim ~~47~~, wherein the antibody is a single chain antibody.

³
~~39~~ ~~96~~. (New) The method of claim ~~47~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

³
~~40~~ ~~97~~. (New) The method of claim ~~47~~, wherein the antibody is conjugated to a chemotherapeutic agent.

⁴⁰
~~41~~ ~~98~~. (New) The method of claim ~~97~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

⁴¹
~~42~~ ~~99~~. (New) The antibody of claim ~~98~~, wherein the agent is a maytansinoid.

⁴
~~43~~ ~~100~~. (New) The method according to claim ~~48~~, wherein the subject is human.

⁴
~~44~~ ~~101~~. (New) The method according to claim ~~48~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

⁴⁵~~102~~. (New) The method of claim ⁴~~48~~, wherein the antibody is a humanized antibody.

⁴⁶~~103~~. (New) The method of claim ⁴~~48~~, wherein the antibody is a human antibody.

⁴⁷~~104~~. (New) The method of claim ⁴~~48~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

⁴⁸~~105~~. (New) The method of claim ⁴~~48~~, wherein the antibody is a full length antibody.

⁴⁹~~106~~. (New) The method of claim ⁴~~48~~, wherein the antibody is a single chain antibody.

⁵⁰~~107~~. (New) The method of claim ⁴~~48~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

⁵¹~~108~~. (New) The method of claim ⁴~~48~~, wherein the antibody is conjugated to a chemotherapeutic agent.

⁵²~~109~~. (New) The method of claim 108, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

⁵³~~110~~. (New) The antibody of claim ⁵²~~109~~, wherein the agent is a maytansinoid.

⁵⁴~~111~~. (New) The method according to claim ⁸~~62~~, wherein the subject is human.

⁵⁵~~112~~. (New) The method according to claim ⁸~~62~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

~~56~~ ~~113~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is a humanized antibody.

~~57~~ ~~114~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is a human antibody.

~~58~~ ~~115~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

~~59~~ ~~116~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is a full length antibody.

~~60~~ ~~117~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is a single chain antibody.

~~61~~ ~~118~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

~~62~~ ~~119~~ ⁸ (New) The method of claim ~~62~~, wherein the antibody is conjugated to a chemotherapeutic agent.

~~63~~ ~~120~~ ⁶² (New) The method of claim ~~119~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

~~64~~ ~~121~~ ⁶³ (New) The antibody of claim ~~120~~, wherein the agent is a maytansinoid.

~~65~~ ~~122~~ ¹⁶ (New) The method according to claim ~~120~~, wherein the subject is human.

~~66~~ ~~123~~ ¹⁶ (New) The method according to claim ~~120~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

¹⁶
~~67~~ ~~124~~. (New) The method of claim ~~70~~, wherein the antibody is a humanized antibody.

¹⁶
~~68~~ ~~125~~. (New) The method of claim ~~70~~, wherein the antibody is a human antibody.

¹⁶
~~69~~ ~~126~~. (New) The method of claim ~~70~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

¹⁶
~~70~~ ~~127~~. (New) The method of claim ~~70~~, wherein the antibody is a full length antibody.

¹⁶
~~71~~ ~~128~~. (New) The method of claim ~~70~~, wherein the antibody is a single chain antibody.

¹⁷
~~72~~ ~~129~~. (New) The method according to claim ~~71~~, wherein the subject is human.

¹⁷
~~73~~ ~~130~~. (New) The method according to claim ~~71~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

¹⁷
~~74~~ ~~131~~. (New) The method of claim ~~71~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

¹⁷
~~75~~ ~~132~~. (New) The method of claim ~~71~~, wherein the antibody is a full length antibody.

¹⁷
~~76~~ ~~133~~. (New) The method of claim ~~71~~, wherein the antibody is a single chain antibody.

¹⁷
~~77~~ ~~134~~. (New) The method of claim ~~71~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

¹⁷
78 ~~135~~. (New) The method of claim ~~71~~, wherein the antibody is conjugated to a chemotherapeutic agent.

⁷⁸
79 ~~136~~. (New) The method of claim ~~135~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

⁷⁹
80 ~~137~~. (New) The antibody of claim ~~136~~, wherein the agent is a maytansinoid.

¹⁸
81 ~~138~~. (New) The method according to claim ~~72~~, wherein the subject is human.

¹⁸
82 ~~139~~. (New) The method according to claim ~~72~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

¹⁸
83 ~~140~~. (New) The method of claim ~~72~~, wherein the antibody is a humanized antibody.

¹⁸
84 ~~141~~. (New) The method of claim ~~72~~, wherein the antibody is a human antibody.

¹⁸
85 ~~142~~. (New) The method of claim ~~72~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

¹⁸
86 ~~143~~. (New) The method of claim ~~72~~, wherein the antibody is a full length antibody.

¹⁸
87 ~~144~~. (New) The method of claim ~~72~~, wherein the antibody is a single chain antibody.

¹⁸
88 ~~145~~. (New) The method of claim ~~72~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

89 146. (New) The method of claim 72, wherein the antibody is conjugated to a chemotherapeutic agent.

90 147. (New) The method of claim 146, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

91 148. (New) The antibody of claim 147, wherein the agent is a maytansinoid.

92 149. (New) The method according to claim 73, wherein the subject is human.

93 150. (New) The method according to claim 73, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

94 151. (New) The method of claim 73, wherein the antibody is a humanized antibody.

95 152. (New) The method of claim 73, wherein the antibody is a human antibody.

96 153. (New) The method of claim 73, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

97 154. (New) The method of claim 73, wherein the antibody is a full length antibody.

98 155. (New) The method of claim 73, wherein the antibody is a single chain antibody.

99 156. (New) The method of claim 73, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

100 ¹⁹ ~~157~~. (New) The method of claim ~~73~~, wherein the antibody is conjugated to a chemotherapeutic agent.

101 ¹⁰⁰ ~~158~~. (New) The method of claim ~~157~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

102 ¹⁰¹ ~~159~~. (New) The antibody of claim ~~158~~, wherein the agent is a maytansinoid.

103 ²⁰ ~~160~~. (New) The method according to claim ~~74~~, wherein the subject is human.

104 ²⁰ ~~161~~. (New) The method according to claim ~~74~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

105 ²⁰ ~~162~~. (New) The method of claim ~~74~~, wherein the antibody is a humanized antibody.

106 ²⁰ ~~163~~. (New) The method of claim ~~74~~, wherein the antibody is a human antibody.

107 ²⁰ ~~164~~. (New) The method of claim ~~74~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

108 ²⁰ ~~165~~. (New) The method of claim ~~74~~, wherein the antibody is a full length antibody.

109 ²⁰ ~~166~~. (New) The method of claim ~~74~~, wherein the antibody is a single chain antibody.

110 ²⁰ ~~167~~. (New) The method of claim ~~74~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

20
111 ~~168~~. (New) The method of claim ~~74~~, wherein the antibody is conjugated to a chemotherapeutic agent.

112 ~~169~~. (New) The method of claim ~~168~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

112
113 ~~170~~. (New) The antibody of claim ~~169~~, wherein the agent is a maytansinoid.

21
114 ~~171~~. (New) The method according to claim ~~75~~, wherein the subject is human.

21
115 ~~172~~. (New) The method according to claim ~~75~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

21
116 ~~173~~. (New) The method of claim ~~75~~, wherein the antibody is a humanized antibody.

21
117 ~~174~~. (New) The method of claim ~~75~~, wherein the antibody is a human antibody.

21
118 ~~175~~. (New) The method of claim ~~75~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

21
119 ~~176~~. (New) The method of claim ~~75~~, wherein the antibody is a full length antibody.

21
120 ~~177~~. (New) The method of claim ~~75~~, wherein the antibody is a single chain antibody.

21
121 ~~178~~. (New) The method of claim ~~75~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

²¹
~~122~~ ~~179~~. (New) The method of claim ~~75~~, wherein the antibody is conjugated to a chemotherapeutic agent.

¹²²
~~123~~ ~~180~~. (New) The method of claim ~~179~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

¹²³
~~124~~ ~~181~~. (New) The antibody of claim ~~180~~, wherein the agent is a maytansinoid.

²²
~~125~~ ~~182~~. (New) The method according to claim ~~76~~, wherein the subject is human.

²²
~~126~~ ~~183~~. (New) The method according to claim ~~76~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

²²
~~127~~ ~~184~~. (New) The method of claim ~~76~~, wherein the antibody is a humanized antibody.

²²
~~128~~ ~~185~~. (New) The method of claim ~~76~~, wherein the antibody is a human antibody.

²²
~~129~~ ~~186~~. (New) The method of claim ~~76~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

²²
~~130~~ ~~187~~. (New) The method of claim ~~76~~, wherein the antibody is a full length antibody.

²²
~~131~~ ~~188~~. (New) The method of claim ~~76~~, wherein the antibody is a single chain antibody.

²²
~~132~~ ~~189~~. (New) The method of claim ~~76~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

133 190. (New) The method of claim 76, wherein the antibody is conjugated to a chemotherapeutic agent.

134 191. (New) The method of claim 190, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

135 192. (New) The antibody of claim 191, wherein the agent is a maytansinoid.

136 193. (New) The method according to claim 77, wherein the subject is human.

137 194. (New) The method according to claim 77, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

138 195. (New) The method of claim 77, wherein the antibody is a humanized antibody.

139 196. (New) The method of claim 77, wherein the antibody is a human antibody.

140 197. (New) The method of claim 77, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

141 198. The method of claim 77, wherein the antibody is a full length antibody.

142 199. (New) The method of claim 77, wherein the antibody is a single chain antibody.

143 200. (New) The method of claim 77, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

144 201. (New) The method of claim 77, wherein the antibody is conjugated to a chemotherapeutic agent.

145 202. (New) The method of claim 201, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

146 203. (New) The antibody of claim 202, wherein the agent is a maytansinoid.

147 204. (New) The method according to claim 81, wherein the subject is human.

148 205. (New) The method according to claim 81, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

149 206. (New) The method of claim 81, wherein the antibody is a humanized antibody.

150 207. (New) The method of claim 81, wherein the antibody is a human antibody.

151 208. (New) The method of claim 81, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

152 209. (New) The method of claim 81, wherein the antibody is a full length antibody.

153 210. (New) The method of claim 81, wherein the antibody is a single chain antibody.

154 211. (New) The method of claim 81, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

155 212. (New) The method of claim 81, wherein the antibody is conjugated to a chemotherapeutic agent.

¹⁵⁵
~~156~~ 213. (New) The method of claim ~~212~~¹⁵⁵, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

¹⁵⁶
~~157~~ 214. (New) The antibody of claim ~~213~~¹⁵⁶, wherein the agent is a maytansinoid.

²⁵
~~158~~ 215. (New) The method according to claim ~~82~~²⁵, wherein the subject is human.

²⁵
~~159~~ 216. (New) The method according to claim ~~82~~²⁵, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

²⁵
~~160~~ 217. (New) The method of claim ~~82~~²⁵, wherein the antibody is a humanized antibody.

²⁵
~~161~~ 218. (New) The method of claim ~~82~~²⁵, wherein the antibody is a human antibody.

²⁵
~~162~~ 219. (New) The method of claim ~~82~~²⁵, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

²⁵
~~163~~ 220. (New) The method of claim ~~82~~²⁵, wherein the antibody is a full length antibody.

²⁵
~~164~~ 221. (New) The method of claim ~~82~~²⁵, wherein the antibody is a single chain antibody.

²⁶
~~165~~ 222. (New) The method according to claim ~~83~~²⁶, wherein the subject is human.

²⁶
~~166~~ 223. (New) The method according to claim ~~83~~²⁶, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

~~167~~ ²⁶
~~224~~. (New) The method of claim ~~83~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab'; and a F(ab')₂ fragment.

~~168~~ ²⁶
~~225~~. (New) The method of claim ~~83~~, wherein the antibody is a full length antibody.

~~169~~ ²⁶
~~226~~. (New) The method of claim ~~83~~, wherein the antibody is a single chain antibody.

~~170~~ ²⁶
~~227~~. (New) The method of claim ~~83~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

~~171~~ ²⁶
~~228~~. (New) The method of claim ~~83~~, wherein the antibody is conjugated to a chemotherapeutic agent.

~~172~~ ¹⁷¹
~~229~~. (New) The method of claim ~~228~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

~~173~~ ¹⁷²
~~230~~. (New) The antibody of claim ~~229~~, wherein the agent is a maytansinoid.

~~174~~ ²⁷
~~231~~. (New) The method according to claim ~~84~~, wherein the subject is human.

~~175~~ ²⁷
~~232~~. (New) The method according to claim ~~84~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

~~176~~ ²⁷
~~233~~. (New) The method of claim ~~84~~, wherein the antibody is a humanized antibody.

~~177~~ ²⁷
~~234~~. (New) The method of claim ~~84~~, wherein the antibody is a human antibody.

²⁷
~~178~~ ²³⁵ (New) The method of claim ~~84~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

²⁷
~~179~~ ²³⁶ (New) The method of claim ~~84~~, wherein the antibody is a full length antibody.

²⁷
~~180~~ ²³⁷ (New) The method of claim ~~84~~, wherein the antibody is a single chain antibody.

²⁷
~~181~~ ²³⁸ (New) The method of claim ~~84~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

²⁷
~~182~~ ²³⁹ (New) The method of claim ~~84~~, wherein the antibody is conjugated to a chemotherapeutic agent.

¹⁸²
~~183~~ ²⁴⁰ (New) The method of claim ~~239~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

¹⁸³
~~184~~ ²⁴¹ (New) The antibody of claim ~~240~~, wherein the agent is a maytansinoid.

²⁸
~~185~~ ²⁴² (New) The method according to claim ~~85~~, wherein the subject is human.

²⁸
~~186~~ ²⁴³ (New) The method according to claim ~~85~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

²⁸
~~187~~ ²⁴⁴ (New) The method of claim ~~85~~, wherein the antibody is a humanized antibody.

²⁸
~~188~~ ²⁴⁵ (New) The method of claim ~~85~~, wherein the antibody is a human antibody.

¹⁸⁹₂₄₆ ²⁸ (New) The method of claim ~~85~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

¹⁹⁰₂₄₇ ²⁸ (New) The method of claim ~~85~~, wherein the antibody is a full length antibody.

¹⁹¹₂₄₈ ²⁸ (New) The method of claim ~~85~~, wherein the antibody is a single chain antibody.

¹⁹²₂₄₉ ²⁸ (New) The method of claim ~~85~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

¹⁹³₂₅₀ ²⁸ (New) The method of claim ~~85~~, wherein the antibody is conjugated to a chemotherapeutic agent.

¹⁹⁴₂₅₁ ¹⁹³ (New) The method of claim ~~250~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

¹⁹⁵₂₅₂ ¹⁹⁴ (New) The antibody of claim ~~251~~, wherein the agent is a maytansinoid.

¹⁹⁶₂₅₃ ²⁹ (New) The method according to claim ~~86~~, wherein the subject is human.

¹⁹⁷₂₅₄ ²⁹ (New) The method according to claim ~~86~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

¹⁹⁸₂₅₅ ²⁹ (New) The method of claim ~~86~~, wherein the antibody is a humanized antibody.

¹⁹⁹₂₅₆ ²⁹ (New) The method of claim ~~86~~, wherein the antibody is a human antibody.

200 ²⁹ ~~257~~. (New) The method of claim ~~86~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

201 ²⁹ ~~258~~. (New) The method of claim ~~86~~, wherein the antibody is a full length antibody.

202 ²⁹ ~~259~~. (New) The method of claim ~~86~~, wherein the antibody is a single chain antibody.

203 ²⁹ ~~260~~. (New) The method of claim ~~86~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

204 ²⁹ ~~261~~. (New) The method of claim ~~86~~, wherein the antibody is conjugated to a chemotherapeutic agent.

205 ²⁰⁴ ~~262~~. (New) The method of claim ~~261~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

206 ²⁰⁵ ~~263~~. (New) The antibody of claim ~~262~~, wherein the agent is a maytansinoid.

207 ³⁰ ~~264~~. (New) The method according to claim ~~87~~, wherein the subject is human.

208 ³⁰ ~~265~~. (New) The method according to claim ~~87~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

209 ³⁰ ~~266~~. (New) The method of claim ~~87~~, wherein the antibody is a humanized antibody.

210 ³⁰ ~~267~~. (New) The method of claim ~~87~~, wherein the antibody is a human antibody.

- 211 ³⁰ 268. (New) The method of claim ~~87~~³⁰, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.
- 212 ³⁰ 269. (New) The method of claim ~~87~~³⁰, wherein the antibody is a full length antibody.
- 213 ³⁰ 270. (New) The method of claim ~~87~~³⁰, wherein the antibody is a single chain antibody.
- 214 ³⁰ 271. (New) The method of claim ~~87~~³⁰, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.
- 215 ³⁰ 272. (New) The method of claim ~~87~~³⁰, wherein the antibody is conjugated to a chemotherapeutic agent.
- 216 ²¹⁵ 273. (New) The method of claim ~~272~~²¹⁵, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.
- 217 ²¹⁶ 274. (New) The antibody of claim ~~273~~²¹⁶, wherein the agent is a maytansinoid.
- 218 ³¹ 275. (New) The method according to claim ~~88~~³¹, wherein the subject is human.
- 219 ³¹ 276. (New) The method according to claim ~~88~~³¹, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.
- 220 ³¹ 277. (New) The method of claim ~~88~~³¹, wherein the antibody is a humanized antibody.
- 221 ³¹ 278. (New) The method of claim ~~88~~³¹, wherein the antibody is a human antibody.

~~222~~ ³¹
~~279~~ (New) The method of claim ~~88~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

~~223~~ ³¹
~~280~~ (New) The method of claim ~~88~~, wherein the antibody is a full length antibody.

~~224~~ ³¹
~~281~~ (New) The method of claim ~~88~~, wherein the antibody is a single chain antibody.

~~225~~ ³¹
~~282~~ (New) The method of claim ~~88~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

~~226~~ ³¹
~~283~~ (New) The method of claim ~~88~~, wherein the antibody is conjugated to a chemotherapeutic agent.

~~227~~ ²²⁶
~~284~~ (New) The method of claim ~~283~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

~~228~~ ²²⁷
~~285~~ (New) The antibody of claim ~~284~~, wherein the agent is a maytansinoid.